Sensitivity analysis demonstrated that in IRS-H patients, anti-PD-(L)1 + chemotherapy versus PD-(L)1 rwPFS were more similar in NSCLC [aHR 1.21 (95% CI, 0.69–2.12), P = 0.51] versus other tumor types [aHR 2.34 (95% CI, 0.996–5.71), P = 0.051], with the non-NSCLC analysis limited by the smaller number of PD-(L)1 treatments, consistent with the earlier line anti-PD-(L)1 + chemotherapy indications [vs. PD-(L)1 monotherapy] and lower IRS-H rates (Fig. 3C; ref. 20) in these tumor types versus NSCLC. The gene discussed is CD274; the disease is neoplasm.